Logo of AdAlta (ASX:1AD)Latest AdAlta (ASX:1AD) News

Page 3
Page 3 of 6

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

AdAlta Secures EW-001 CAR-T Rights and Advances Manufacturing with FDA Engagement in Sight

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.
Ada Torres
29 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

AdAlta Clears US$1M Milestone to Unlock BZDS1901 Data and Australian Manufacturing

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.
Ada Torres
1 July 2026

Healthcare Wrap - Week 22 (25 May -> 29 May) 2026

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
Logan Eniac
30 May 2026

AdAlta Taps FDA Expertise to Fast-Track CAR-T Therapy for Mesothelioma

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.
Ada Torres
25 May 2026

Market Wrap - Week 19 (4 May -> 8 May) 2026

Gold explorers and small-cap tech names drove the biggest share price swings this week, while one healthcare stock sank after a deeply discounted funding move. Deals, drill hits and fresh financing dominated trading across the ASX.
Logan Eniac
9 May 2026

Healthcare Wrap - Week 19 (4 May -> 8 May) 2026

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.
Logan Eniac
9 May 2026

AdAlta Raises A$2.5M to Advance CAR-T Therapy BZDS1901 with FDA and Manufacturing Milestones

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.
Ada Torres
4 May 2026

Market Wrap - Week 18 (27 Apr -> 1 May) 2026

Small caps drove the biggest moves, with Alvo Minerals surging, Klevo extending a payments-fuelled rally, and FBR jumping on fresh contract news. At the larger end, takeover bids, mine funding deals and a strong Liontown update kept resources and corporate activity at the centre of trading.
Logan Eniac
2 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

AdAlta Advances CAR-T Therapy with East-to-West Strategy and Australian Manufacturing Transfer

AdAlta has launched its East-to-West cellular immunotherapy strategy through a co-development deal for CAR-T therapy BZDS1901, showing promising complete tumour clearance in mesothelioma patients and transferring manufacturing to Australia to boost scalability.
Ada Torres
30 Apr 2026